Secretory carcinoma of the breast, commonly exhibits the features of low grade, triple negative breast carcinoma- A Case report with updated review of literature

Banerjee, Nirmalya; Banerjee, Devmalya; Choudhary, Neha

doi:10.4322/acr.2020.227

Cited by 8 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The imaging features of SBC are similar to those of other well-defined benign breast tumors (2,(21)(22)(23). In contrast to invasive ductal carcinoma (IDC), on mammography, SBC has a variety of nonspecific features, ranging from discontinuous, lobulated, isolated, benignlooking masses with smooth or irregular edges to suspicious asymmetric densities with speculated margins, but rarely microcalcifications (11).…”

Section: Clinical Manifestationsmentioning

confidence: 84%

“…Another 2 ETV6 - NTRK3 fusion-positive SBC cases showed a good response to pan-TKI ( 30 ). There is currently no report of entrectonib for ETV6 - NTRK3 fusion-positive SBC ( 23 ). The first-generation TKIs have so far been known to have two kinds of drug resistance: targeted resistance and off-target resistance, while the second-generation TKIs can overcome the drug resistance of the first generation TKIs ( 85 , 86 ).…”

Section: Treatment and Prognosismentioning

confidence: 99%

See 1 more Smart Citation

Advancement of secretory breast carcinoma: a narrative review

Min¹,

Zhu²,

Liu³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background and Objective: Secretory breast carcinoma (SBC) is a rare breast malignancy. Most available studies on SBC are case reports or small case series, and the few large-sample studies available lack critical information due to database limitations. To improve the understanding of SBC and provide a reference for clinical practice, we systematically reviewed the demographic, clinical, pathologic, and genetic characteristics of SBC, as well as its treatment and prognosis.Methods: We conducted a PubMed search with the keywords "secretory breast carcinoma" or "juvenile breast carcinoma". Relevant English-language publications published from January 1966 to February 2022 were screened manually at 3 levels-title, abstract, and full text-to identify the articles that presented the demographic, clinical, pathologic, and genetic characteristics of SBC, as well as its treatment and prognosis.Key Content and Findings: SBC lacks specific clinical manifestations and has typical pathological and molecular characteristics, including intracellular and extracellular eosinophilic secretions, immune spectrum similar to hormone receptor-positive tumors, and the ETV6-NTRK3 fusion gene. Surgery remains the primary treatment for SBC. Postoperative radiotherapy is recommended by most researchers for adult SBC but not for pediatric patients. The evidence of chemotherapy and endocrine therapy is insufficient, and targeted therapy of the ETV6-NTRK3 fusion gene shows a good response. Most patients with SBC have a good prognosis except for a few patients who experience distant metastases. Future studies will be focused on the molecular characteristics of those patients with SBC who have a poor prognosis. Conclusions:The development of histopathology and molecular genetics has promoted the progress of the clinical diagnosis of SBC. The purpose of this review is to serve as a guide for the better clinical treatment of SBC, particularly in the areas of disease identification and prognosis classification for patients.

show abstract

Section: Clinical Manifestationsmentioning

confidence: 84%

Section: Treatment and Prognosismentioning

confidence: 99%

Advancement of secretory breast carcinoma: a narrative review

Min¹,

Zhu²,

Liu³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“…The originally issued pathology diagnoses were invasive ductal carcinoma not otherwise specified, but it was clear on a secondary expert review that the carcinomas were of the secretory type. Whether this revised classification of SBC would have impacted treatment for her early disease is not certain as there is limited data on the benefit of chemotherapy and radiation 23 24. Further investigation on the most appropriate treatment paradigm for this tumour subtype is needed.…”

Section: Discussionmentioning

confidence: 99%

Metastatic triple negative breast cancer with NTRK gene fusion on tissue but not on ctDNA molecular profile

Singh

Decker

et al. 2022

BMJ Case Rep

View full text Add to dashboard Cite

A woman presented to medical oncology with almost 4 years of untreated, slowly progressing, triple negative metastatic breast cancer to the lung. About 15 years prior, she was diagnosed with invasive ductal carcinoma of the right breast with ipsilateral chest wall recurrence 6 years later. Comprehensive molecular profiling of a metastatic lesion detected a hotspotETV6-NTRK3fusion, which was not present on circulating tumour DNA or molecular profile performed 4 years prior. A second look pathological examination demonstrated tumour characteristics consistent with secretory breast carcinoma. Identification ofETV6-NKRT3fusion allowed for treatment with larotrectinib, a tyrosine kinase inhibitor specifically indicated for secretory breast carcinoma. After 3 months, she experienced a partial response.

show abstract

“…A panel of IHC markers, including ER, PR, HER2, Ki-67, S-100 and Pan-TRK [ 2 , 23 – 25 ], may serve as a useful tool to aid the diagnosis of SCB. Initial studies have shown that SBC is usually triple negative or weakly positive for hormone receptors with S-100 positive expression [ 26 – 28 ]. With further research, we found that cases with moderate or even strong ER positivity also existed and that S-100 is expression is not specific to SBCs [ 4 , 5 , 27 ].…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological features and genomic profiles of a group of secretory breast carcinomas in which progressive cases have more complex genomic features

et al. 2022

View full text Add to dashboard Cite

Background Secretory breast carcinoma (SBC) is a rare malignant breast neoplasm with distinct histological features, including solid, microcystic, tubular, and rarely papillary structures, traditionally characterized by a t (12;15) (p13:q25) translocation, which usually leads to ETV6-NTRK3 fusion, suggesting an early event in tumorigenesis. Due to the rarity of this disease, very few genome sequencing studies have been performed on a series of cases, especially progressive cases. Methods Seven lesions from 5 patients diagnosed at the Third Affiliated Hospital of Soochow University from 2007 to 2021 were included. Clinicopathological features and prognosis/survival data were collected. Next-generation DNA sequencing was performed on six of the seven lesions. Results In total, 3/7 (42.9%) lesions demonstrated estrogen receptor (ER) expression, including weak, moderate to strong staining, and no lesion demonstrated progesterone receptor (PR) expression. There were no cases of human epidermal growth factor (HER2) overexpression, and the Ki-67 index was low. S-100 and pan-TRK protein were diffusely positively expressed in all cases. All lesions were characterized by a t(12;15) (p13:q25) translocation, leading to ETV6-NTRK3 fusion confirmed by fluorescence in situ hybridization (FISH). The sequencing results showed that ETV6-NTRK3 fusion was the main driver of early tumorigenesis, while SBC with invasive biological behavior had more complex genomic variation in which TERT promoter mutation was detected. Conclusions Immunohistochemical staining of a biomarker panel, including ER, PR, HER2, Ki-67, S-100 and pan-TRK, can be used as an auxiliary diagnostic tool, and FISH detection can be used as a diagnostic tool. ETV6-NTRK3 gene fusion involving multiple sites may drive tumorigenesis, while mutations in the TERT promoter region may be a factor driving tumor progression.

show abstract

Secretory carcinoma of the breast, commonly exhibits the features of low grade, triple negative breast carcinoma- A Case report with updated review of literature

Cited by 8 publications

References 22 publications

Advancement of secretory breast carcinoma: a narrative review

Advancement of secretory breast carcinoma: a narrative review

Metastatic triple negative breast cancer with NTRK gene fusion on tissue but not on ctDNA molecular profile

Clinicopathological features and genomic profiles of a group of secretory breast carcinomas in which progressive cases have more complex genomic features

Contact Info

Product

Resources

About